Exchange & Returns Information
Review Details
(0)
| Generic For | POMALYST |
|---|---|
| Active Ingredient | POMALIDOMIDE |
| Strength | 2MG |
| Manufacturer | HETERO DRUGS |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 21 CAPSULES | $ 2.00 | $ 42.00 |
$ 35.70
Apply ZARVY26 (-15%)
You save $ 6.30
|
||
| 2 BOXES - 42 CAPSULES | $ 2.14 | $ 90.00 |
$ 76.50
Apply ZARVY26 (-15%)
You save $ 13.50
|
||
| ★ Best Value 3 BOXES - 63 CAPSULES | $ 2.21 | $ 139.00 |
$ 118.15
Apply ZARVY26 (-15%)
You save $ 20.85
|
Reference information will be available soon.
Pomide 2 is a 2 mg capsule formulation of pomalidomide, a potent third-generation immunomodulatory drug (IMiD) developed for the treatment of advanced hematologic malignancies. As a thalidomide derivative, it demonstrates enhanced immunomodulatory, anti-angiogenic, and direct cytotoxic properties. The medication is primarily indicated for relapsed or refractory multiple myeloma (RRMM) and is also being increasingly investigated in Kaposi’s sarcoma and off-label hematologic indications. Owing to its lower strength, Pomide 2 is particularly suitable for patients who cannot tolerate higher doses or those requiring dose adjustments during therapy.
AntiCancer Drugs > Relapsed or Refractory Multiple Myeloma
Pomide 2 is recommended for patients who have failed at least two prior regimens, including lenalidomide and a proteasome inhibitor. In combination with low-dose dexamethasone, it significantly improves progression-free survival and overall response rates in this difficult-to-treat population.
> Triple-Class Refractory MM
For patients who no longer respond to IMiDs, proteasome inhibitors, and anti-CD38 monoclonal antibodies, pomalidomide serves as an essential last-line therapy. It is also used in investigational combination regimens with agents like daratumumab or carfilzomib to overcome multi-drug resistance in aggressive myeloma.
> Kaposi’s Sarcoma
Pomide 2 is approved for use in both HIV-positive and HIV-negative adults with Kaposi’s sarcoma (KS), particularly in cases unresponsive to antiretroviral therapy. Its anti-angiogenic activity directly targets KS lesions, which are highly dependent on blood vessel proliferation.
> Investigational Use in Lymphomas and Leukemias
Pomalidomide is being studied in T-cell lymphomas and chronic lymphocytic leukemia (CLL). Clinical trials are exploring its ability to modulate the tumor microenvironment and to act synergistically with other hematologic agents in refractory disease settings.
Pomalidomide enhances T-cell and natural killer (NK) cell responses while suppressing pro-inflammatory cytokines. It also blocks the formation of new blood vessels (anti-angiogenesis) and inhibits myeloma cell growth. Through these combined actions, it provides disease stabilization in advanced-stage malignancies, particularly in patients whose disease has progressed despite prior therapies. Its use is increasingly considered in salvage regimens and in resistant phenotypes of multiple myeloma.
For multiple myeloma, the usual adult dose is 4 mg orally once daily on Days 1 through 21 of each 28-day cycle. It must be administered in combination with dexamethasone and continued until disease progression or development of unacceptable toxicity.
For Kaposi’s sarcoma, the recommended adult dose is 5 mg orally once daily on Days 1 through 21 of each 28-day cycle. Treatment should be continued until disease progression or unacceptable toxicity. In HIV-positive patients, HAART therapy should be maintained concurrently.
Additional Instructions:
Patients should take the medication at the same time each day, with water, on an empty stomach. Use during pregnancy is strictly contraindicated due to the high teratogenic risk. Regular monitoring of blood counts and liver function is essential. Thromboprophylaxis should be considered for patients at increased risk of venous thromboembolism.
Store at room temperature (below 25°C) in a dry place, protected from light. Keep capsules in original blister packaging. Avoid handling opened or broken capsules directly.
Common adverse effects include neutropenia, thrombocytopenia, anemia, fatigue, constipation, and upper respiratory infections. Serious risks include thromboembolic events, hepatotoxicity, and secondary primary malignancies. Monitoring is essential to mitigate long-term toxicity.
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
